Theralase Technologies Inc. V.TLT

Ho hum, 6 for 6, 100% Efficacy!!! But others are doing!!!!!

[macman1519]

Cannabis is medicine. As the use of medicinal cannabis becomes a fact of life in not only North America, but the world, it is now widely recognized that cannabinoids (the active ingredients in the cannabis plant) have numerous medicinal applications.

Many cannabis companies are producing dried flower and related products for use as medicine, and more and more often, these products are being officially prescribed by licensed physicians. This is greatly beneficial to the patients using medicinal cannabis as well as being profitable for cannabis companies.

How do investors see the profits from such cannabinoid medications increase? Through patent protection. The “Patent Cliff” is an operational and financial nightmare for the pharmaceutical industry. In 2017 alone; Big Pharma faced the loss of patent protection on licensed drugs with total revenues of $26.5 billion.

These multinational drug companies have never been hungrier for new patent-protected drugs, to replenish their drug pipelines – and their bottom lines. As drug development costs soar, more and more often Big Pharma is choosing to buy patent-protected drugs rather than meeting those development needs organically.

One Company that is looking to cash-in on the opportunities presented by the Patent Cliff is India Globalization Capital Inc. (NYSE Market: IGC, Forum). IGC describes itself as a “cannabis pharmaceutical company”, entering the cannabis space in 2013. On April 10, 2018, the Company announced the filing of its eighth U.S. patent application.

India Globalization Capital has pioneered the development of Hyalolex, a cannabinoid-based treatment aimed at alleviating many of the symptoms suffered by Alzheimer’s patients. A drug industry publication from October 2017 predicts sales of Alzheimer’s disease treatments to reach $14.8 billion by 2026.

image: https://www.stockhouse.com/getattachment/64168edb-1bf6-4025-af8c-abe8ee4388a0/igc_alzheimers.png

Stockhouse recently had the opportunity to learn more about this latest development as well as India Globalization Capital’s overall operations from IGC’s CEO, Ram Mukunda.

 
Please introduce new investors to India Globalization Capital Inc.

We are listed on the NYSE American with the ticker “IGC”.  Our structure consists of two lines of business: 1) a legacy International trading business with offices in India and 2) a medical cannabis business with offices in the U.S.  We have developed a flagship product for alleviating many of the symptoms of Alzheimer’s known as Hyalolex.   We believe that this product will bring relief to patients suffering from Alzheimer’s as well as reduce associated caregiver distress.  The formulation is based on many years of research conducted at the University of South Florida and we expect to roll out this product to 10 U.S. states by the end of this year.
    
 
Let’s first dive right into your latest news: the filing of another patent in your pursuit for a cannabinoid treatment for Alzheimer’s disease. Precisely to what does this patent relate?

After years of research, we produced a liquid compound that contains a unique mix of natural products including THC at very specific dosing levels.   Our patent filing seeks to protect the method of preparation and the composition of the formulation.

 
IGC’s lead cannabinoid pharmaceutical product is Hyalolex. Please explain what Hyalolex is and the time and effort that has been spent to date in developing this cannabinoid pharmaceutical product.

Producing this formulation took about seven years of research, and includes testing on Alzheimer’s cell lines, Alzheimer’s mice, and people.  For example, one test involved measuring how long it would take regular mice to navigate a water maze.  The results showed that it took mice with Alzheimer’s twice as long to navigate the maze as Alzheimer’s mice treated with the medication.  Another study shows that one of the active ingredients in the formulation helped reduce plaque buildup in the brain.  Plaques are considered to be a hallmark of Alzheimer’s.

The full background surrounding the research effort can be found on our website, www.hyalolex.com


Now please tell investors what Hyalolex does.

Alzheimer’s patients suffer from a variety of disorders and symptoms.  For example, they suffer from plaque buildup in the brain, damage to mitochondrial functioning, neuronal death, loss of memory, anxiety, aggression, sleep disorder.   And in general there is a lot of caregiver distress as the patient’s disease advances.   Hyalolex helps alleviate these symptoms.  For example, a patient suffering from Alzheimer’s may suffer from anxiety and sleep disorder, Hyalolex can help reduce anxiety and help them sleep better.  It helps the patient and in turn helps caregivers.

Read more at https://www.stockhouse.com/opinion/interviews/2018/04/18/patent-filed-for-cannabis-based-alzheimer-s-treatment#iPuHBqcPQQAOMPeG.99